ASCO 2020 | ADAURA: osimertinib post-tumor resection in NSCLC

Roy Herbst, MD, PhD, FACP, FASCO, Yale University, New Haven, CT, talks about the data from the ADAURA study (NCT02511106) in which patients with stage IB–IIIA EGFR mutation positive non-small cell lung cancer (NSCLC) were treated with osimertinib as adjuvant therapy after complete tumor resection. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).